VTV ended 2023 with a total return of 10% compared to the S&P 500 and VOOG's total returns of 24% and 31%. In fact, the value category traded in the red for most of the year before the year-end rally.

Third Quarter 2024 Financial Results Cash Position: The Company’s cash position as of September 30, 2024, was $41.6 million compared to $9.4 million as of December 31, 2023.

Second Quarter 2024 Financial Results Cash Position: The Company’s cash position as of June 30, 2024, was $45.5 million compared to $9.4 million as of December 31, 2023.

Detailed Fundamental Analysis - VTV November 11, 2024 — 07:00 am EST Written by John Reese for Validea -> Below is Validea's ETF fundamental report for Vanguard Value ETF (VTV).

vTv Therapeutics' Phase 3 trial for cadisegliatin in type 1 diabetes resumes after FDA lifts hold, with a revised six-month timeline to accelerate key studies.